


# Should we consider low LDL-cholesterol a marker of in-hospital bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention?

Diana A. Gorog <sup>1,2\*</sup>, Eliano P. Navarese<sup>3,4</sup>, and Felicita Andreotti <sup>5,6</sup>

<sup>1</sup>Postgraduate Medical School, University of Hertfordshire, Hatfield, UK; <sup>2</sup>National Heart and Lung Institute, Imperial College, London, UK; <sup>3</sup>Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland; <sup>4</sup>Faculty of Medicine, University of Alberta, Edmonton, Canada; <sup>5</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; and <sup>6</sup>Cardiovascular Medicine, Catholic University, Rome, Italy

Online publish-ahead-of-print 29 July 2021

This editorial refers to ‘Low-density lipoprotein cholesterol levels and in-hospital bleeding in patients treated with high-intensity antithrombotic therapy: findings from the CCC-ACS Project’, by Q. Yang *et al.*, doi:10.1093/eurheartj/ehab418.



In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), there is increasing awareness of the need to balance the benefits of antithrombotic therapy against the risks of major bleeding.<sup>1</sup> Non-coronary artery bypass graft-related major bleeding is reported to occur in up to 1–3% per annum of patients with ACS treated with dual antiplatelet therapy (DAPT) and is independently associated with mortality. Major bleeding may be more frequent in East Asian populations, with contemporary data indicating up to 3% per annum major bleeding with DAPT.<sup>2</sup> Moreover, registry-based contemporary data suggest that bleeding in 'real-world' clinical practice may be more prevalent, with up to 4–5% of patients with ACS experiencing in-hospital bleeding.<sup>3</sup>

A number of studies have assessed ways of mitigating the bleeding risk in ACS patients undergoing PCI, by reducing the potency or duration of DAPT. However, a significant challenge is identifying which patients are at increased bleeding risk, as many patient-related characteristics shown to increase bleeding risk also increase ischaemic risk, including advancing age, chronic kidney disease, anaemia, and white blood cell count.<sup>1</sup> There are currently no reliable, easily available, validated biomarkers to specifically identify patients at excess bleeding risk.

In this issue of the *European Heart Journal*, Yang and colleagues<sup>4</sup> report an association between admission serum LDL cholesterol (LDL-C) and major in-hospital bleeds in a large Chinese nationwide registry involving 42 378 ACS patients treated with PCI from 2014 to 2019 receiving intensive antithrombotic therapy. Major bleeding was defined as the composite of (i) Bleeding Academic Research Consortium (BARC) type 3b–3c and type 5 bleeding; (ii) Thrombolysis In Myocardial Infarction (TIMI) major bleeding; and (iii) PLATElet inhibition and patient Outcomes (PLATO) life-threatening major bleeding. The authors of this retrospective analysis report a non-linear association between LDL-C levels and major in-hospital bleeds or net clinical outcome, with higher risk of bleeding, including haemorrhagic stroke, associated with lower LDL-C levels, after controlling for 48 baseline covariates. A threshold for the increased risk of adverse outcomes in this population was identified at LDL-C <70 mg/dL. Whilst the normal/high and low LDL-C groups differed with regard to most baseline risk factors, the association of low LDL-C with bleeding held after propensity score matching. Most patients were on clopidogrel as part of DAPT, and use of ticagrelor in 32% of patients enhanced the low LDL-C-associated bleeding risk, compared with clopidogrel. Roughly a third of patients received a glycoprotein IIb/IIIa inhibitor (an unusually high rate especially in an East Asian population who are prone to bleeding), yet subgroup analysis suggests that admission LDL-C <70 mg/dL was only associated with non-procedural bleeds, predominantly gastrointestinal. Notwithstanding the limitations of a retrospective analysis, this is the first very large cohort study indicating an adverse association of low LDL-C levels with excess bleeding in Chinese patients with ACS, and the findings are worthy of further discussion.

A causative relationship between LDL-C levels and increased bleeding risk cannot be inferred from this study, which is observational by design and may be prone to confounding or reverse causality. Whilst propensity score matching was performed with a large number of covariate adjustments, this does not entirely neutralize the marked differences between the two cohorts (those with low LDL-C vs. normal or high LDL-C), suggesting that LDL-C alone cannot

explain the excess bleeding and that the latter is likely to be multifactorial. Indeed, patients with low LDL-C had multiple risk factors for increased bleeding, compared with those with higher LDL-C, including more advanced age, lower body mass index (BMI), and more frequent renal failure, and were more often treated pre-hospital with aspirin and a P2Y<sub>12</sub> inhibitor. The lower BMI of patients with low LDL-C compared with that of patients with normal or high LDL-C levels is an important limitation, as low body weight is a strong harbinger of bleeding and other adverse outcomes (obesity paradox).<sup>1,5</sup> Thus, lower LDL-C might be a proxy for a sicker cohort with more comorbidities, or of patients who may, perhaps, have been pre-treated with high-dose statins, thereby identifying those with pre-established cardiovascular disease. Indeed, patients with lower LDL-C more often had undergone prior PCI than the higher LDL-C counterparts (17.5% vs 6.6%), and P2Y<sub>12</sub> inhibitors were used more often before admission (25.6% vs. 15.0%).

Residual questions relate to the reliability of bleeding event diagnosis, as this was locally and not centrally adjudicated, and to the generalizability to non-Chinese populations. Some previous studies in predominantly Western populations have identified low LDL-C as a predictor of bleeding in chronic coronary syndrome.<sup>6</sup>

Findings from other studies support a possible causal association, reporting a relationship between lower levels of non-HDL-C, in particular low LDL-C levels, and an increased risk of intracranial haemorrhage (ICH).<sup>7</sup> In particular, in Chinese individuals, there appears to be an inverse association between LDL-C level and ICH, confirmed by genetic analyses and by LDL-C-lowering trials.<sup>8</sup> Recent data from 316 428 individuals enrolled in the UK Biobank, together with 1286 patients with ICH and matched controls, showed that genetically elevated LDL levels were associated with a lower risk of ICH, with one standard deviation increase in total cholesterol [odds ratio (OR) 0.92] or LDL-C (OR 0.88) significantly inversely associated with ICH risk.<sup>9</sup> A nested case-control study within the prospective China Kadoorie Biobank involving ~5000 patients with ICH showed that an elevated LDL-C level was inversely associated with risk of ICH.<sup>8</sup> In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which focused on high-dose atorvastatin for secondary prevention after a first stroke or transient ischaemic attack, post-hoc analysis revealed an unexpected increment in ICH with active treatment compared with placebo, although no relationship with entry LDL-C levels was observed.<sup>10</sup>

The above relationship remains controversial, given the reported safety of very low (<30 mg/dL) LDL-C levels in a setting of non-intensive antithrombotic therapy. A recent meta-analysis of randomized controlled trials did not find an association between low LDL-C and haemorrhagic stroke, in line with previous studies.<sup>11</sup> The use of the PCSK9 [proprotein convertase subtilisin kexin 9] inhibitor alirocumab in >18 000 patients with recent ACS, whilst significantly reducing LDL-C, did not increase the risk of ICH during a 2.8-year follow-up.<sup>12</sup>

Could this association of low LDL-C with bleeding be causal with a plausible mechanism? Histopathological studies have suggested that lower cholesterol concentrations may increase the permeability of the vessel walls.<sup>13</sup> In a mechanistic *in vitro* study, cholesterol depletion reduced mean platelet volume, granularity, and platelet ATP release, and inhibited platelet aggregation by altering platelet ultrastructure critical in mediating secretion.<sup>14</sup> In a small study of patients with

coronary disease undergoing apheresis, a 58% reduction in LDL-C was also associated with a 52% reduction in fibrinogen and lipoprotein(a), and a significant reduction in shear stress-dependent platelet adhesion.<sup>15</sup> In a single-blind crossover study to assess the effect of lipoprotein apheresis compared with sham apheresis on markers of thrombosis and fibrinolysis, lipoprotein apheresis reduced shear-induced occlusive platelet thrombus formation and enhanced endogenous fibrinolysis, without corresponding changes with sham treatment.<sup>16</sup> In addition, lipoprotein apheresis, but not sham treatment, reduced von Willebrand factor and fibrinogen, with no change in D-dimer, thrombin/antithrombin complex, or thrombin generation assay with either apheresis or sham treatment.

The study by Yang and colleagues should stimulate further prospective studies to examine the relationship between serum LDL-C and bleeding, especially among patients receiving intensive antithrombotic therapy, as well as those managed without percutaneous intervention. A longer term analysis, including the DAPT treatment period, or in patients on oral anticoagulation, would also be important. Furthermore, this study included exclusively Chinese patients; since bleeding risk is acknowledged to be higher in East Asians compared with those from other ethnic backgrounds, further analysis to examine this possible association in other populations would be important. Furthermore, as shown in a large Swedish national database registry of patients with ST-elevation ACS, the absence of well-recognized modifiable risk factors for ACS (hypertension, diabetes, hypercholesterolaemia, and smoking) identifies a cohort at high mortality risk.<sup>17</sup>

While the magnitude of benefit of LDL-C reduction in patients with ACS undergoing PCI should trump concerns over lipid-lowering strategies (the average in-hospital TIMI major bleeding rates were <1.5% and 2% in the lowest LDL-C categories), low LDL-C on admission among ACS patients undergoing PCI may be a marker of increased susceptibility to bleeding during intensive antithrombotic therapy. Thus, every effort should be made to reduce the risk of bleeding, including with the use of gastrointestinal prophylaxis, radial rather than femoral artery access, good blood pressure control, anti-coagulant or parenteral antiplatelet dosing adjusted to weight and renal function, and careful choice of antithrombotic drugs (*Graphical Abstract*).

**Conflict of interest:** none declared.

## References

1. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand J-P, Caterina RD, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KAA, Kristensen SD, Rao SV, Verheugt FWA, Widimský P, Zeymer U, Collet JP. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. *Eur Heart J* 2011;**32**:1854–1864.
2. Kim B-K, Hong S-J, Cho Y-H, Yun KH, Kim YH, Suh Y, Cho JY, Her A-Y, Cho S, Jeon DW, Yoo S-Y, Cho D-K, Hong B-K, Kwon H, Ahn C-M, Shin D-H, Nam C-M, Kim J-S, Ko Y-G, Choi D, Hong M-K, Jang Y; TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome. *JAMA* 2020;**323**:2407–2416.
3. Peyracchia M, Saglietto A, Biolè C, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, Ariza-Solé A, Liebetrau C, Manzano-Fernández S, Boccuzzi G, Henriques JPS, Wilton SB, Velicki L, Xanthopoulos I, Correia L, Rognoni A, Fabrizio U, Nuñez-Gil I, Montabone A, Taha S, Fujii T, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Kawaji T, Blanco PF, Garay A, Quadri G, Queija BC, Huczek Z, Paz RC, González-Juanatey JR, Fernández MC, Nie SP, D'Amico M, Pousa IM, Kawashiri MA, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Lopez-Cuenca A, Cequier A, Alexopoulos D, Iñiguez-Romo A, Grossomarra W, Usmiani T, Rinaldi M, D'Ascenzo F. Efficacy and safety of clopidogrel, prasugrel and ticagrelor in ACS patients treated with PCI: a propensity score analysis of the RENAMI and BleeMACS registries. *Am J Cardiovasc Drug* 2020;**20**:259–269.
4. Yang Q, Sun D, Pei C, Zeng Y, Wang Z, Li Z, Hao Y, Song X, Li Y, Liu G, Tang Y, Smith SC Jr, Han Y, Huo Y, Ge J, Ma C, Fonarow GC, Morgan L, Liu J, Liu J, Zhou M, Zhao D, Zhou Y, Zhou X; CCC-ACS Investigators. Low-density lipoprotein cholesterol levels and in-hospital bleeding in patients treated with high-intensity antithrombotic therapy: findings from the CCC-ACS Project. *Eur Heart J* 2021;**42**:3175–3186.
5. Andreotti F, Rio T, Lavorgna A. Body fat and cardiovascular risk: understanding the obesity paradox. *Eur Heart J* 2009;**30**:752–754.
6. Ducrocq G, Wallace JS, Baron G, Ravaut P, Alberts MJ, Wilson PWF, Ohman EM, Brennan DM, D'Agostino RB, Bhatt DL, Steg PG; REACH Investigators. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. *Eur Heart J* 2010;**31**:1257–1265.
7. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke. *Stroke* 2013;**44**:1833–1839.
8. Sun L, Clarke R, Bennett D, Guo Y, Walters RG, Hill M, Parish S, Millwood IY, Bian Z, Chen Y, Yu C, Lv J, Collins R, Chen J, Peto R, Li L, Chen Z; China Kadoorie Biobank Collaborative Group; International Steering Committee; International Co-ordinating Centre, Oxford; National Co-ordinating Centre, Beijing; Regional Co-ordinating Centres. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. *Nat Med* 2019;**25**:569–574.
9. Falcone GJ, Kirsch E, Acosta JN, Noche RB, Leasure A, Marini S, Chung J, Selim M, Meschia JF, Brown DL, Worrall BB, Tirschwell DL, Jagiella JM, Schmidt H, Jimenez-Conde J, Fernandez-Cadenas I, Lindgren A, Slowik A, Gill D, Holmes M, Phuah C, Petersen NH, Matouk Md CN, Gunel M, Sansing L, Bennett D, Chen Z, Sun LL, Clarke R, Walters RG, Gill TM, Biffi A, Kathiresan S, Langefeld CD, Woo D, Rosand J, Sheth KN, Anderson CD; International Stroke Genetics Consortium. Genetically elevated LDL associates with lower risk of intracerebral hemorrhage. *Ann Neurol* 2020;**88**:56–66.
10. Goldstein LB, Amarencu P, Szarek M, Callahan A, Hennerici M, Sillese H, Zivin JA, Welch KMA; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. *Neurology* 2008;**70**:2364–2370.
11. Masson W, Lobo M, Siniawski D, Masson G, Lavalle-Cobo A, Molinero G. LDL-C levels below 55 mg/dl and risk of hemorrhagic stroke: a meta-analysis. *J Stroke Cerebrovasc Dis* 2021;**30**:105655.
12. Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, Goodman SG, Kim Y-U, Pordy R, Reiner Z, Roe MT, Tse H-F, Valdovinos PCM, White HD, Zeiher AM, Szarek M, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Investigators. Effect of alirocumab on stroke in ODYSSEY OUTCOMES. *Circulation* 2019;**140**:2054–2062.
13. Konishi M, Iso H, Komachi Y, Iida M, Shimamoto T, Jacobs DR Jr, Terao A, Baba S, Sankai T, Ito M. Associations of serum total cholesterol, different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. *Stroke* 2018;**49**:954–964.
14. Grgurevich S, Krishnan R, White MM, Jennings LK. Role of *in vitro* cholesterol depletion in mediating human platelet aggregation. *J Thromb Haemost* 2003;**1**:576–586.
15. Spieker LE, Ruschitzka F, Badimon JJ, Noll G, Corti R. Shear stress-dependent platelet function after LDL cholesterol apheresis. *Thromb Res* 2004;**113**:395–398.
16. Khan TZ, Gorog DA, Arachchilage DJ, Ahnström J, Rhodes S, Donovan J, Banya W, Pottle A, Barbir M, Pennell DJ. Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): findings from a randomized controlled cross-over trial. *J Clin Lipidol* 2019;**13**:788–796.
17. Figtree GA, Vernon ST, Hadziomsanovic N, Sundström J, Alfredsson J, Arnott C, Delatour V, Leósdóttir M, Hagström E. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. *Lancet* 2021;**397**:1085–1094.